A New Blood Test May Help Detect Early Kidney Damage in Children with Type 1 Diabetes

Researchers found that a protein called FABP1 in the blood shows promise as an early warning sign of kidney damage in children with Type 1 diabetes, potentially catching problems before current standard tests do.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

diagnosisscreeningautoantibodiesstaging

Key takeaways

FABP1, a protein released from kidney cells when they're damaged, was significantly higher in children with diabetic kidney disease compared to those without it
This new biomarker may complement existing tests like microalbuminuria, which can miss early kidney damage
A blood test measuring FABP1 correctly identified kidney disease in children about 63% of the time and correctly ruled it out about 73% of the time in this small study
More research is needed before FABP1 testing becomes a standard part of kidney disease screening

Why Early Detection of Kidney Damage Matters

Diabetic kidney disease is one of the most serious long-term complications of Type 1 diabetes and a leading cause of chronic kidney disease worldwide. Catching kidney damage early—before permanent scarring occurs—gives the best chance for slowing or preventing further harm.

Currently, doctors screen for kidney disease using a test called the albumin-creatinine ratio, which measures protein leaking into urine. However, this test often only becomes abnormal after significant kidney damage has already occurred. Scientists are looking for earlier warning signs that could alert families and doctors to tubular damage—the initial injury that happens in the kidney's filtration units.

What This Study Found

Researchers in this study measured a protein called FABP1 (fatty acid-binding protein 1) in the blood of 90 children: 30 with Type 1 diabetes and kidney disease, 30 with Type 1 diabetes but no kidney disease, and 30 children without diabetes.

FABP1 levels were significantly higher in children with established kidney disease compared to those without it. The protein also correlated with other markers of kidney stress, including cholesterol levels. Using a cutoff level of 189 ng/L, the FABP1 test correctly identified kidney disease about 63% of the time and correctly ruled it out about 73% of the time.

What This Means—and What It Doesn't

This is early-stage research suggesting FABP1 could be a useful complementary tool alongside existing kidney disease screening. It does not mean the test is ready for routine clinical use. The study was small, and the test's accuracy needs improvement before it becomes standard in medical practice.

If future research confirms these findings in larger groups of children, FABP1 might one day help doctors identify kidney damage earlier, potentially opening a window for intervention before permanent injury occurs. For now, families should continue regular kidney disease screening as recommended by their care team, which currently includes urine and blood tests to monitor kidney function.

Evidence label

Source: European journal of pediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.